These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 24004943)

  • 1. A cost-effectiveness analysis of a 10-valent pneumococcal conjugate vaccine in children in six Latin American countries.
    Martí SG; Colantonio L; Bardach A; Galante J; Lopez A; Caporale J; Knerer G; Gomez JA; Augustovski F; Pichon-Riviere A
    Cost Eff Resour Alloc; 2013 Aug; 11(1):21. PubMed ID: 24004943
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness and cost utility analysis of three pneumococcal conjugate vaccines in children of Peru.
    Gomez JA; Tirado JC; Navarro Rojas AA; Castrejon Alba MM; Topachevskyi O
    BMC Public Health; 2013 Oct; 13():1025. PubMed ID: 24171921
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of conjugate pneumococcal vaccination in Singapore: comparing estimates for 7-valent, 10-valent, and 13-valent vaccines.
    Tyo KR; Rosen MM; Zeng W; Yap M; Pwee KH; Ang LW; Shepard DS
    Vaccine; 2011 Sep; 29(38):6686-94. PubMed ID: 21745516
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness evaluation of the 10-valent pneumococcal non-typeable
    Lu CY; Chung CH; Huang LM; Kruger E; Tan SC; Zhang XH; Chiu NC
    Cost Eff Resour Alloc; 2020; 18():30. PubMed ID: 32874139
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness analysis of a universal mass vaccination program with a PHiD-CV 2+1 schedule in Malaysia.
    Wang XJ; Saha A; Zhang XH
    Cost Eff Resour Alloc; 2017; 15():17. PubMed ID: 28852326
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness analysis of routine pneumococcal vaccination in the UK: a comparison of the PHiD-CV vaccine and the PCV-13 vaccine using a Markov model.
    Delgleize E; Leeuwenkamp O; Theodorou E; Van de Velde N
    BMJ Open; 2016 Nov; 6(11):e010776. PubMed ID: 27903558
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modeling the impact of a new vaccine on pneumococcal and nontypable Haemophilus influenzae diseases: a new simulation model.
    De Wals P; Black S; Borrow R; Pearce D
    Clin Ther; 2009 Oct; 31(10):2152-69. PubMed ID: 19922887
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness analysis of infant pneumococcal vaccination with PHiD-CV in Korea.
    Zhang XH; Leeuwenkamp O; Oh KB; Lee YE; Kim CM
    Hum Vaccin Immunother; 2018 Jan; 14(1):85-94. PubMed ID: 29115905
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estimated Annual Health and Cost Impact of PHiD-CV Immunization Program in Brazil.
    Gomez JA; Lopes de Abreu AJ; Caceres DC; Nieto J; Ortega-Barria E
    Pediatr Infect Dis J; 2019 Oct; 38(10):e260-e265. PubMed ID: 31568144
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity and safety of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) co-administered with DTPa vaccine in Japanese children: A randomized, controlled study.
    Iwata S; Kawamura N; Kuroki H; Tokoeda Y; Miyazu M; Iwai A; Oishi T; Sato T; Suyama A; François N; Shafi F; Ruiz-Guiñazú J; Borys D
    Hum Vaccin Immunother; 2015; 11(4):826-37. PubMed ID: 25830489
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overall effectiveness of pneumococcal conjugate vaccines: An economic analysis of PHiD-CV and PCV-13 in the immunization of infants in Italy.
    Castiglia P; Pradelli L; Castagna S; Freguglia V; Palù G; Esposito S
    Hum Vaccin Immunother; 2017 Oct; 13(10):2307-2315. PubMed ID: 28700264
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Economic Impact of Pneumococcal Protein-D Conjugate Vaccine (PHiD-CV) on the Malaysian National Immunization Programme.
    Aljunid S; Maimaiti N; Ahmed Z; Muhammad Nur A; Md Isa Z; Azmi S; Sulong S
    Value Health Reg Issues; 2014 May; 3():146-155. PubMed ID: 29702920
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-Effectiveness Evaluation of the 10-Valent Pneumococcal Non-typeable Haemophilus influenzae Protein D Conjugate Vaccine and 13-Valent Pneumococcal Vaccine in Japanese Children.
    Shiragami M; Mizukami A; Leeuwenkamp O; Mrkvan T; Delgleize E; Kurono Y; Iwata S
    Infect Dis Ther; 2014 Dec; 4(1):93-112. PubMed ID: 25527448
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Cost-Effectiveness Analysis of the 10-Valent Pneumococcal Non-Typeable Haemophilus influenzae Protein D Conjugate Vaccine (PHiD-CV) Compared to the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) for Universal Mass Vaccination Implementation in New Zealand.
    Varghese L; Talbot L; Govender A; Zhang XH; Mungall BA
    Appl Health Econ Health Policy; 2018 Jun; 16(3):331-345. PubMed ID: 29633160
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcomes and costs associated with PHiD-CV, a new protein D conjugate pneumococcal vaccine, in four countries.
    Talbird SE; Taylor TN; Knoll S; Frostad CR; García Martí S
    Vaccine; 2010 Nov; 28 Suppl 6():G23-9. PubMed ID: 21075266
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estimating the cost-effectiveness of an infant 13-valent pneumococcal conjugate vaccine national immunization program in China.
    Shen K; Wasserman M; Liu D; Yang YH; Yang J; Guzauskas GF; Wang BCM; Hilton B; Farkouh R
    PLoS One; 2018; 13(7):e0201245. PubMed ID: 30044865
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-Effectiveness Comparison of Pneumococcal Conjugate Vaccines in Turkish Children.
    Marijam A; Olbrecht J; Ozakay A; Eken V; Meszaros K
    Value Health Reg Issues; 2019 Sep; 19():34-44. PubMed ID: 30776766
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Can two different pneumococcal conjugate vaccines be used to complete the infant vaccination series? A randomized trial exploring interchangeability of the 13-valent pneumococcal conjugate vaccine and the pneumococcal non-typeable
    de Los Santos AM; Rodríguez-Weber MA; Sánchez-Márquez P; Traskine M; Carreño-Manjarrez R; Cervantes-Apolinar MY; Strezova A; Ruiz-Guiñazú J; Ortega-Barria E; Borys D
    Expert Rev Vaccines; 2020 Nov; 19(11):995-1010. PubMed ID: 33297773
    [No Abstract]   [Full Text] [Related]  

  • 19. Cost effectiveness of adding 7-valent pneumococcal conjugate (PCV-7) vaccine to the Norwegian childhood vaccination program.
    Wisløff T; Abrahamsen TG; Bergsaker MA; Løvoll Ø; Møller P; Pedersen MK; Kristiansen IS
    Vaccine; 2006 Jul; 24(29-30):5690-9. PubMed ID: 16735083
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety, reactogenicity and immunogenicity of 2-dose catch-up vaccination with 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in Malian children in the second year of life: Results from an open study.
    Dicko A; Dicko Y; Barry A; Sidibe Y; Mahamar A; Santara G; Dolo A; Diallo A; Doumbo O; Shafi F; François N; Yarzabal JP; Strezova A; Borys D; Schuerman L
    Hum Vaccin Immunother; 2015; 11(9):2207-14. PubMed ID: 26020101
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.